Oppenheimer Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $95.00

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price objective trimmed by Oppenheimer from $98.00 to $95.00 in a research note published on Tuesday,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

Other equities analysts have also issued research reports about the stock. Canaccord Genuity Group raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price target for the company from $84.00 to $98.00 in a report on Tuesday, January 20th. Barclays started coverage on BioMarin Pharmaceutical in a report on Wednesday, January 28th. They issued an “overweight” rating and a $80.00 price target for the company. Wall Street Zen cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. HC Wainwright increased their target price on BioMarin Pharmaceutical from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, December 22nd. Finally, Stifel Nicolaus restated a “hold” rating and set a $61.00 target price (down from $73.00) on shares of BioMarin Pharmaceutical in a report on Thursday, November 6th. Fifteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $87.71.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $61.11 on Tuesday. The company has a current ratio of 5.21, a quick ratio of 3.10 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $11.74 billion, a P/E ratio of 34.33, a PEG ratio of 0.52 and a beta of 0.26. The business has a 50-day moving average of $58.90 and a 200-day moving average of $56.15. BioMarin Pharmaceutical has a 1 year low of $50.76 and a 1 year high of $73.51.

Insider Activity at BioMarin Pharmaceutical

In related news, EVP Gregory R. Friberg sold 6,326 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the sale, the executive vice president owned 37,578 shares in the company, valued at approximately $2,268,959.64. This represents a 14.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BMRN. River Road Asset Management LLC bought a new stake in BioMarin Pharmaceutical in the 4th quarter valued at $53,865,000. Pacer Advisors Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 53.6% during the fourth quarter. Pacer Advisors Inc. now owns 937,356 shares of the biotechnology company’s stock worth $55,707,000 after buying an additional 327,204 shares in the last quarter. Wick Capital Partners LLC bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $73,000. Corient Private Wealth LLC boosted its position in shares of BioMarin Pharmaceutical by 159.5% in the fourth quarter. Corient Private Wealth LLC now owns 15,145 shares of the biotechnology company’s stock valued at $900,000 after acquiring an additional 9,309 shares during the period. Finally, Mercer Global Advisors Inc. ADV grew its stake in shares of BioMarin Pharmaceutical by 1.4% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 64,069 shares of the biotechnology company’s stock valued at $3,808,000 after acquiring an additional 910 shares in the last quarter. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Wells Fargo called BMRN an attractive buy ahead of the Transcon‑CNP PDUFA, signaling investor interest around the upcoming regulatory decision. Wells Fargo Buy Note
• Positive Sentiment: Sanford C. Bernstein raised its price target from $90 to $94 and kept an outperform rating — a direct positive signal from a major sell‑side shop. Bernstein PT Raise (Benzinga)
• Positive Sentiment: Analysis pieces argue that recent share rebound and DCF assumptions may still imply upside for BMRN, supporting a constructive view for longer‑term investors. Pricing / DCF Upside Analysis
• Neutral Sentiment: Analysts broadly revised forecasts after Q4 results; the coverage is mixed and driving headline activity but not a uniform consensus. Analyst Revisions (Benzinga)
• Neutral Sentiment: BioMarin’s Q4 earnings call highlights were released; investors will parse guidance and R&D updates for implications on cash runway and upcoming catalysts. Q4 Earnings Call Highlights
• Neutral Sentiment: Short‑interest reports flagged a “large increase,” but the filings in the feed show inconsistent/zero values (NaN/0), making the short‑interest signal unreliable for now; not a clear driver.
• Negative Sentiment: HC Wainwright cut its price target to $55 and moved to a neutral rating, a downgrade that reduces near‑term sentiment given the lower target relative to recent levels. HC Wainwright PT Cut (Benzinga)
• Neutral Sentiment: Guggenheim trimmed its target from $106 to $86 but kept a buy rating; Oppenheimer also lowered its target to $95 — mixed signals that compress consensus and increase short‑term volatility. Guggenheim / Oppenheimer Coverage (Benzinga / AmericanBankingNews) Read More.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.